en
E-mail us
cn

Determination and Control of Crystal Form in ASD Formulations: A Case Study on Everolimus Tablets

Amorphous solid dispersion (ASD) molecularly disperses a drug in a polymer matrix to form an amorphous solid solution or suspension, improving apparent solubility and oral bioavailability. Because the amorphous state is thermodynamically less stable and prone to recrystallization, rigorous control of crystal form is essential to prevent loss of performance. This case study outlines the strategy used to develop and control the amorphous solid dispersion of everolimus, focusing on crystalline-phase quantitation and limit-setting.

Access the Full Content
By submitting this form, you acknowledge that your information will be used to provide the requested content and may be processed as described in our Privacy Policy.
Contact Us
bd_global@crystalpharmatech.com (925) 558-5040
U.S
NJ Sites: Suite 500-B, 3000 Eastpark Blvd, Cranbury, New Jersey, USA 08512
2005 Eastpark Blvd, Cranbury, New Jersey, USA 08512
CA Site: 7133 Koll Center Parkway, Suite 200, Pleasanton, California, USA 94566
Canada
6800 Kitimat Rd, Unit 1, Mississauga, Ontario, Canada L5N 5M1
China
No. 288, Jiangyun Road, Suzhou Industrial Park, Suzhou, China 215123

Subscribe to be the first to get the updates!

Subscribe to be the first to get the updates!
NJ Sites: Suite 500-B, 3000 Eastpark Blvd, Cranbury, New Jersey, USA 08512
2005 Eastpark Blvd, Cranbury, New Jersey, USA 08512
CA Site: 7133 Koll Center Parkway, Suite 200, Pleasanton, California, USA 94566
bd_global@crystalpharmatech.com (925) 558-5040
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. Part of the tracking is necessary to ensure SEO effectiveness,
By using this site, you agree to our use of cookies. Visit our cookie policy to learn more.
Reject Accept